Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
China SXT Pharmaceuticals Inc (SXTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: SXTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.76% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 199.57M USD | Price to earnings Ratio 0.01 | 1Y Target Price - |
Price to earnings Ratio 0.01 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.1 | 52 Weeks Range 0.95 - 11.92 | Updated Date 06/29/2025 |
52 Weeks Range 0.95 - 11.92 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 124.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 318.69% | Operating Margin (TTM) -76.95% |
Management Effectiveness
Return on Assets (TTM) 18.15% | Return on Equity (TTM) 57.63% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value 190144853 | Price to Sales(TTM) 109.75 |
Enterprise Value 190144853 | Price to Sales(TTM) 109.75 | ||
Enterprise Value to Revenue 104.57 | Enterprise Value to EBITDA 29.92 | Shares Outstanding 116028000 | Shares Floating 488309 |
Shares Outstanding 116028000 | Shares Floating 488309 | ||
Percent Insiders 0.02 | Percent Institutions 0.01 |
Upturn AI SWOT
China SXT Pharmaceuticals Inc
Company Overview
History and Background
China SXT Pharmaceuticals Inc. was founded to focus on the development, manufacturing, marketing, and sales of Traditional Chinese Medicine (TCM) products. The company aims to leverage TCM principles to provide healthcare solutions.
Core Business Areas
- TCM Products: Development, manufacture, and sales of traditional Chinese medicine products for various health conditions.
Leadership and Structure
Details of leadership team and organizational structure were not discoverable via public sources.
Top Products and Market Share
Key Offerings
- Traditional Chinese Medicine Formulations: Various TCM formulations. Market share data unavailable. Competitors include other TCM manufacturers and distributors in China.
Market Dynamics
Industry Overview
The TCM industry in China is large and growing, driven by increasing demand for natural and holistic healthcare solutions. However, it is also highly competitive and subject to strict regulatory oversight.
Positioning
China SXT's positioning within the industry is not determinable without further information. Key to its market presence is its product portfolio and distribution network.
Total Addressable Market (TAM)
Total Addressable Market (TAM) data for the Chinese TCM market is not easily discoverable without specialized market research. China SXT's positioning depends on their products, manufacturing capabilities and distribution.
Upturn SWOT Analysis
Strengths
- TCM Product Portfolio
- Established Manufacturing Facilities
- Knowledge of TCM Principles
Weaknesses
- Limited Market Share
- Dependence on Chinese Market
- Brand Recognition Challenges
Opportunities
- Expanding TCM product lines
- Entering new geographical markets
- Partnerships with established healthcare providers
Threats
- Stringent regulatory environment
- Increased competition from other TCM providers
- Fluctuations in raw material costs
Competitors and Market Share
Key Competitors
Competitive Landscape
Competitive advantages and disadvantages relative to competitors are unknown.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are difficult to assess without financial and performance data.
Future Projections: Future growth projections cannot be provided without adequate financial analysis.
Recent Initiatives: Recent strategic initiatives cannot be determined without access to company announcements.
Summary
Information regarding the company is very scarce. Without access to financials, competitive data, and market share it is nearly impossible to provide a good understanding of China SXT Pharmaceuticals. More information regarding the company's recent performance is needed to provide a comprehensive analysis. China SXT Pharmaceuticals is a small business in a competitive environment in which it needs to establish an edge to grow.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available information
Disclaimers:
The information provided is based on limited available data and may not be entirely accurate. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About China SXT Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-01-04 | Chairman of the Board & Co-CEO Mr. Feng Zhou | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 75 | Website https://www.sxtchina.com |
Full time employees 75 | Website https://www.sxtchina.com | ||
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.